Changepoint modeling of longitudinal PSA as a biomarker for prostate cancer
From MaRDI portal
Recommendations
- Combining longitudinal studies of PSA
- Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach
- Prostate cancer: Progression of prostate-specific antigen after external beam irradiation
- Modeling biomarker dynamics with implications for the treatment of prostate cancer
Cited in
(9)- Prostate cancer: Progression of prostate-specific antigen after external beam irradiation
- Modeling of the pH- and the temperature-dependant deviations of the free to total PSA (prostate specific antigen) ratios for clinical predictability of prostate cancer and benign prostate hyperplasia
- A comparative study of approaches for predicting prostate cancer from longitudinal data
- Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
- Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach
- Change-point cure models with application to estimating the change-point effect of age of diagnosis among prostate cancer patients
- Screening for prostate cancer using multivariate mixed-effects models
- Combining longitudinal studies of PSA
- Estimating the optimal time to perform a positron emission tomography with prostate-specific membrane antigen in prostatectomized patients, based on data from clinical practice
This page was built for publication: Changepoint modeling of longitudinal PSA as a biomarker for prostate cancer
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4385372)
